Find Niraparib Tosylate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

42RELATED EXCIPIENT COMPANIES

56EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1038915-73-9, Mk-4827 tosylate, Mk-4827 (tosylate), Mk-4827-tosylate, Niraparib (tosylate), Mk 4827 tosylate
Molecular Formula
C26H28N4O4S
Molecular Weight
492.6  g/mol
InChI Key
LCPFHXWLJMNKNC-PFEQFJNWSA-N
FDA UNII
75KE12AY9U

Niraparib Tosylate
1 2D Structure

Niraparib Tosylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-methylbenzenesulfonic acid;2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
2.1.2 InChI
InChI=1S/C19H20N4O.C7H8O3S/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10)/t14-;/m1./s1
2.1.3 InChI Key
LCPFHXWLJMNKNC-PFEQFJNWSA-N
2.1.4 Canonical SMILES
CC1=CC=C(C=C1)S(=O)(=O)O.C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
2.1.5 Isomeric SMILES
CC1=CC=C(C=C1)S(=O)(=O)O.C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
2.2 Other Identifiers
2.2.1 UNII
75KE12AY9U
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1038915-73-9

2. Mk-4827 Tosylate

3. Mk-4827 (tosylate)

4. Mk-4827-tosylate

5. Niraparib (tosylate)

6. Mk 4827 Tosylate

7. Niraparib (mk-4827) Tosylate

8. (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide 4-methylbenzenesulfonate

9. 75ke12ay9u

10. Mk-4827(niraparib) Tosylate

11. 2h-indazole-7-carboxamide, 2-(4-(3s)-3-piperidinylphenyl)-, 4-methylbenzenesulfonate (1:1)

12. Unii-75ke12ay9u

13. Niraparib Tosylate Monohyrate

14. Niraparib(mk-4827) Tosylate

15. Schembl20522624

16. Dtxsid801026487

17. Hy-10619b

18. Mfcd28167748

19. S7625

20. Ccg-269634

21. Niraparib Tosylate [orange Book]

22. Ac-30383

23. As-56981

24. A11848

25. A909268

26. Q27266392

27. (3s)-3-[4-[7-(aminocarbonyl)-2h-indazol-2-yl]phenyl]piperidine Tosylate

28. (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide 4-?methylbenzenesulfona?te

29. 4-methylbenzenesulfonic Acid;2-[4-[(3s)-piperidin-3-yl]phenyl]indazole-7-carboxamide

30. 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; 4-methylbenzene-1-sulfonic Acid

2.4 Create Date
2014-10-10
3 Chemical and Physical Properties
Molecular Weight 492.6 g/mol
Molecular Formula C26H28N4O4S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count4
Exact Mass492.18312656 g/mol
Monoisotopic Mass492.18312656 g/mol
Topological Polar Surface Area136 Ų
Heavy Atom Count35
Formal Charge0
Complexity655
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 1  
Drug NameZEJULA
Active IngredientNIRAPARIB TOSYLATE
CompanyTESARO INC (Application Number: N208447. Patents: 8071623, 8436185)

API SUPPLIERS

read-more
read-more

01

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Dr Reddy Company Banner

02

Shandong Loncom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shandong Loncom Pharmaceutical company banner

03

Porton Pharma Solutions

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

Flag China
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Porton Company Banner

04

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

05

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bioequity Europe
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Bioequity Europe
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Globe Quimica Ltda

Brazil

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bioequity Europe
Not Confirmed
arrow

07

Bulat Pharmaceutical

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bioequity Europe
Not Confirmed
arrow

08

Beijing Hope Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bioequity Europe
Not Confirmed
arrow

09

Dishman Carbogen Amcis

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bioequity Europe
Not Confirmed
arrow

Dishman Carbogen Amcis

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Bioequity Europe
Not Confirmed
USDMF CEP/COS JDMF EU-WCInactive-api NDC arrow-down KDMF VMF Others AUDIT
blank

10

Anhui HaiKang Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bioequity Europe
Not Confirmed
arrow
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

Flag China
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41529

Submission : 2025-03-17

Status : Active

Type : II

Porton Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Niraparib Tosylate

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
Dr Reddy Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content

Niraparib Tosylate

About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...

Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development Zone, Shandong Province, Shandong Loncom has operational API pilot tests and production bases adhering to international standards. With 13 production lines dedicated to oral solid preparations, oral liquid preparations and API, it is actively expanding its preparation workshops for small-volume injections, soft capsules, eye drops, topical medicines and innovative drug R&D centres.
Shandong Loncom Pharmaceutical company banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

Flag China
Digital Content Digital Content

Niraparib Tosylate

About the Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities ar...

Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities are located in China, Slovenia, the US, Belgium, Switzerland, Denmark, with more than 6000 employees worldwide. Porton leads the way with its excellent CDMO services, but also supplies APIs & intermediates for the treatment of critical diseases such as HIV/AIDS, diabetes, cancer, & influenza. Our Process Technology Centers & WHO/USFDA/EMA/PDMA/NMPA-inspected Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets.
Porton Company Banner

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Niraparib Tosylate

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry with over 350 Products portfolio. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Niraparib

About the Company : Beijing Hope Pharmaceutical Co., Ltd., established in 2005, is a high-tech enterprise with "chemical drug research and development" as its core capability. Hope has over 16 years o...

Beijing Hope Pharmaceutical Co., Ltd., established in 2005, is a high-tech enterprise with "chemical drug research and development" as its core capability. Hope has over 16 years of experience in project evaluation, innovation-oriented patent around design, pre-clinical development, clinical trial practice, registration, marker authorization, etc.. Project schedule, quality, life cycle, and registration success rate has been ensured under the orderly and well-defined R&D management system.
blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Niraparib

About the Company : Bulat Pharmaceutical is a fast growing pharmaceutical company, founded in the year 2017, Bulat Pharmaceutical is engaged in the manufacturing and sales of high quality APIs and Int...

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Niraparib

About the Company : Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu Province, China. The company was fou...

Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu Province, China. The company was founded in 1949 by (Tan Ruiting) with a registered capital of 108 million yuan and the company was restructured as a Changzhou pharmaceutical Factory under the aegis of the Shanghai Pharma Group. The company mainly involves leading pharmaceutical manufacturers a wide range of key Intermediates, Active pharmaceutical ingredients, and Finished Formulations that meet with global standards.
blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Niraparib Tosylate

About the Company : Globe Quimica S.A. is a major Brazilian API producer, GMP certificated by ANVISA, manufactures more than 20 different API's such as Antiretrovirals, Anxiolytic, Antidepressant, Ant...

Globe Quimica S.A. is a major Brazilian API producer, GMP certificated by ANVISA, manufactures more than 20 different API's such as Antiretrovirals, Anxiolytic, Antidepressant, Antithrombotic, Analgesic. In 2012 Globe Quimica has started-up its new API plant for Active Ingredients for Oncologic Drugs.
blank

09

Hetero Drugs

India
PEGS Boston Summit
Not Confirmed
arrow

Hetero Drugs

India
arrow
PEGS Boston Summit
Not Confirmed

Niraparib

About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
blank

10

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Niraparib Tosylate

About the Company : ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a w...

ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry.Combining cost-effective resources and productivity of Asia along with unmatched regulatory know-how, ScinoPharm is uniquely positioned to serve global pharmaceutical R&D and manufacturing needs at any level and for any company in this sector.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696962600,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"TO THE ORDER OF","customerCountry":"SLOVENIA","quantity":"0.90","actualQuantity":"0.9","unit":"KGS","unitRateFc":"15000","totalValueFC":"13925.4","currency":"EUR","unitRateINR":1287777.7777777778,"date":"11-Oct-2023","totalValueINR":"1159000","totalValueInUsd":"13925.4","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"4549647","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707849000,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"TO THE ORDER OF.,","customerCountry":"SLOVENIA","quantity":"0.79","actualQuantity":"0.79","unit":"KGS","unitRateFc":"15000","totalValueFC":"12577","currency":"EUR","unitRateINR":1320964.5569620254,"date":"14-Feb-2024","totalValueINR":"1043562","totalValueInUsd":"12577","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"7531776","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707849000,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"TO THE ORDER OF.,","customerCountry":"SLOVENIA","quantity":"2.30","actualQuantity":"2.3","unit":"KGS","unitRateFc":"8000","totalValueFC":"18154.3","currency":"USD","unitRateINR":654927.3913043479,"date":"14-Feb-2024","totalValueINR":"1506333","totalValueInUsd":"18154.3","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"7531791","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715193000,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.09","actualQuantity":"0.09","unit":"KGS","unitRateFc":"30000","totalValueFC":"2617.1","currency":"USD","unitRateINR":2423826.555555556,"date":"09-May-2024","totalValueINR":"218144.39","totalValueInUsd":"2617.1","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"9746080","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715797800,"product":"NIRAPARIB TOSYLATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"17000","totalValueFC":"33552.4","currency":"USD","unitRateINR":1398365,"date":"16-May-2024","totalValueINR":"2796730","totalValueInUsd":"33552.4","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"9924233","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727634600,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"DEVA HOLDING AS","customerCountry":"TURKEY","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"12000","totalValueFC":"11773.4","currency":"USD","unitRateINR":986628.27000000002,"date":"30-Sep-2024","totalValueINR":"986628.27","totalValueInUsd":"11773.4","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"4480196","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731436200,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"MONTREAL-DORAVAL APT","customer":"CANDIAC","customerCountry":"CANADA","quantity":"21.26","actualQuantity":"21.26","unit":"KGS","unitRateFc":"14000","totalValueFC":"293147.3","currency":"USD","unitRateINR":1163601.578080903,"date":"13-Nov-2024","totalValueINR":"24738169.55","totalValueInUsd":"293147.3","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"5562383","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1741113000,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"AMMAN","customer":"HIKMA PHARMACEUTICALS","customerCountry":"JORDAN","quantity":"1.56","actualQuantity":"1.56","unit":"KGS","unitRateFc":"10000","totalValueFC":"15420.4","currency":"USD","unitRateINR":856205.12820512813,"date":"05-Mar-2025","totalValueINR":"1335680","totalValueInUsd":"15420.4","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"8747989","productDescription":"API","marketType":"","country":"JORDAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715365800,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"NATCO HOUSE, ROAD NO.2,","city":"HYDERABAD, A.P.","supplier":"NANTONG CHANYOO PHARMATECH","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"NATCO PHARMA","customerCountry":"INDIA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"13000","totalValueFC":"157863.7","currency":"USD","unitRateINR":"1096550","date":"11-May-2024","totalValueINR":"13158600","totalValueInUsd":"157863.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"3446872","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"NO,2 TONGHAI SI ROAD,YANGKOU CHEMICAL INDUSTRIAL PARK,RUDONG COASTAL,ECOOMIC DEVELOPMENT ZONE,NANTONG CN","customerAddress":"NATCO HOUSE, ROAD NO.2,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720549800,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"CHANGZHOU PHARMACEUTICAL FACTORY","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"0.80","actualQuantity":"0.8","unit":"KGS","unitRateFc":"16500","totalValueFC":"13335.6","currency":"USD","unitRateINR":"1393425","date":"10-Jul-2024","totalValueINR":"1114740","totalValueInUsd":"13335.6","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4430180","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"NO.518, LAO DONG EAST ROAD, CHANGZHOU JIANGSU 213018, CHINA. Changzhou, , China China","customerAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1727721000,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,","city":"HYDERABAD,TELANGANA","supplier":"CHANGZHOU PHARMACEUTICAL FACTORY","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"12000","totalValueFC":"24163.8","currency":"USD","unitRateINR":"1015200","date":"01-Oct-2024","totalValueINR":"2030400","totalValueInUsd":"24163.8","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"5903809","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"NO.518, LAO DONG EAST ROAD, CHANGZH OU JIANGSU 213018, CHINA. Changzhou , , China China","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734719400,"product":"NIRAPARIB TOSYLATE MONOHYDRATE NIRAPARIB TOSYLATE MONOHYDRATE FOR R & D PURPOSE","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"CHANGZHOU PHARMACEUTICAL FACTORY","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"12000","totalValueFC":"36415.6","currency":"USD","unitRateINR":"1031400","date":"21-Dec-2024","totalValueINR":"3094200","totalValueInUsd":"36415.6","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"7380284","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"NO.518, LAO DONG EAST ROAD, CHANGZH OU JIANGSU 213018, CHINA. Changzhou , China China","customerAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1740681000,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"NATCO HOUSE, ROAD NO.2,","city":"HYDERABAD, A.P.","supplier":"NANTONG CHANYOO PHARMATECH","supplierCountry":"CHINA","foreign_port":"SHANGHAI PU DONG APT","customer":"NATCO PHARMA","customerCountry":"INDIA","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"8050","totalValueFC":"324910","currency":"USD","unitRateINR":"706387.5","date":"28-Feb-2025","totalValueINR":"28255500","totalValueInUsd":"324910","indian_port":"Vizag-RPCIPL SEZ","hs_no":"29339990","bill_no":"8618693","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI PU DONG APT","supplierAddress":"NO,2 TONGHAI SI ROAD,YANGKOU CHEMIC AL INDUSTRIAL PARK,RUDONG COASTAL, SDNF China","customerAddress":"NATCO HOUSE, ROAD NO.2,"}]
11-Oct-2023
05-Mar-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.


Lead Product(s): Azenosertib,Niraparib Tosylate

Therapeutic Area: Oncology Brand Name: ZN-c3

Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 09, 2025

blank

01

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.

Product Name : ZN-c3

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 09, 2025

blank
  • Development Update

Details:

Jemperli (dostarlimab, targets PD-1) in combination with Zejula (niraparib, targets PARP) is being evaluated as a first line treatment in phase 3 ciical trials of ovarian cancer.


Lead Product(s): Dostarlimab,Niraparib Tosylate

Therapeutic Area: Oncology Brand Name: Jemperli

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 20, 2024

blank

02

GSK

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

GSK

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Jemperli (dostarlimab, targets PD-1) in combination with Zejula (niraparib, targets PARP) is being evaluated as a first line treatment in phase 3 ciical trials of ovarian cancer.

Product Name : Jemperli

Product Type : Antibody

Upfront Cash : Inapplicable

December 20, 2024

blank

Details:

ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.


Lead Product(s): Azenosertib,Niraparib Tosylate

Therapeutic Area: Oncology Brand Name: ZN-c3

Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 16, 2024

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.

Product Name : ZN-c3

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 16, 2024

blank

Details:

ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.


Lead Product(s): Azenosertib,Niraparib Tosylate

Therapeutic Area: Oncology Brand Name: ZN-c3

Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 18, 2024

blank

04

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.

Product Name : ZN-c3

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 18, 2024

blank
  • Development Update

Details:

Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.


Lead Product(s): Dostarlimab,Niraparib Tosylate

Therapeutic Area: Oncology Brand Name: Jemperli

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 24, 2024

blank

05

GSK

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

GSK

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.

Product Name : Jemperli

Product Type : Antibody

Upfront Cash : Inapplicable

April 24, 2024

blank
  • Development Update

Details:

Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.


Lead Product(s): Dostarlimab,Niraparib Tosylate

Therapeutic Area: Oncology Brand Name: Jemperli

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 16, 2024

blank

06

GSK

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

GSK

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.

Product Name : Jemperli

Product Type : Antibody

Upfront Cash : Inapplicable

March 16, 2024

blank

Details:

Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.


Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Brand Name: Akeega

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Janssen Biotech

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 07, 2024

blank

07

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.

Product Name : Akeega

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

January 07, 2024

blank
  • Development Update

Details:

Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.


Lead Product(s): Dostarlimab,Niraparib Tosylate

Therapeutic Area: Oncology Brand Name: Jemperli

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 18, 2023

blank

08

GSK

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

GSK

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.

Product Name : Jemperli

Product Type : Antibody

Upfront Cash : Inapplicable

December 18, 2023

blank

Details:

KEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with BRCA-positive mCRPC.


Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Brand Name: Akeega

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 08, 2023

blank

09

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : KEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with BRCA-positive mCRPC.

Product Name : Akeega

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

November 08, 2023

blank

Details:

JNJ-64091742 (niraparib) is an orally administered, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor that is currently being studied for the treatment of metastatic castrationresistant prostate cancer with BRCA alterations.


Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Brand Name: Zejula

Study Phase: Phase IIIProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 22, 2023

blank

10

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : JNJ-64091742 (niraparib) is an orally administered, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor that is currently being studied for the treatment of metastatic castrationresistant prostate cancer with BRCA alterations.

Product Name : Zejula

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

October 22, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Lubricants & Glidants

read-more
read-more

Coating Systems & Additives

read-more
read-more

Direct Compression

read-more
read-more

Granulation

read-more
read-more

Co-Processed Excipients

read-more
read-more

Coloring Agents

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Emulsifying Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Parenteral

read-more
read-more

Taste Masking

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1038915-73-9 / Niraparib Tosylate API manufacturers, exporters & distributors?

Niraparib Tosylate manufacturers, exporters & distributors 1

83

PharmaCompass offers a list of Niraparib Tosylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Niraparib Tosylate manufacturer or Niraparib Tosylate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Niraparib Tosylate manufacturer or Niraparib Tosylate supplier.

PharmaCompass also assists you with knowing the Niraparib Tosylate API Price utilized in the formulation of products. Niraparib Tosylate API Price is not always fixed or binding as the Niraparib Tosylate Price is obtained through a variety of data sources. The Niraparib Tosylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Niraparib Tosylate

Synonyms

1038915-73-9, Mk-4827 tosylate, Mk-4827 (tosylate), Mk-4827-tosylate, Niraparib (tosylate), Mk 4827 tosylate

Cas Number

1038915-73-9

Unique Ingredient Identifier (UNII)

75KE12AY9U

Niraparib Tosylate Manufacturers

A Niraparib Tosylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Niraparib Tosylate, including repackagers and relabelers. The FDA regulates Niraparib Tosylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Niraparib Tosylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Niraparib Tosylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Niraparib Tosylate Suppliers

A Niraparib Tosylate supplier is an individual or a company that provides Niraparib Tosylate active pharmaceutical ingredient (API) or Niraparib Tosylate finished formulations upon request. The Niraparib Tosylate suppliers may include Niraparib Tosylate API manufacturers, exporters, distributors and traders.

click here to find a list of Niraparib Tosylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Niraparib Tosylate USDMF

A Niraparib Tosylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Niraparib Tosylate active pharmaceutical ingredient (API) in detail. Different forms of Niraparib Tosylate DMFs exist exist since differing nations have different regulations, such as Niraparib Tosylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Niraparib Tosylate DMF submitted to regulatory agencies in the US is known as a USDMF. Niraparib Tosylate USDMF includes data on Niraparib Tosylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Niraparib Tosylate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Niraparib Tosylate suppliers with USDMF on PharmaCompass.

Niraparib Tosylate WC

A Niraparib Tosylate written confirmation (Niraparib Tosylate WC) is an official document issued by a regulatory agency to a Niraparib Tosylate manufacturer, verifying that the manufacturing facility of a Niraparib Tosylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Niraparib Tosylate APIs or Niraparib Tosylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Niraparib Tosylate WC (written confirmation) as part of the regulatory process.

click here to find a list of Niraparib Tosylate suppliers with Written Confirmation (WC) on PharmaCompass.

Niraparib Tosylate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Niraparib Tosylate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Niraparib Tosylate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Niraparib Tosylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Niraparib Tosylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Niraparib Tosylate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Niraparib Tosylate suppliers with NDC on PharmaCompass.

Niraparib Tosylate GMP

Niraparib Tosylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Niraparib Tosylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Niraparib Tosylate GMP manufacturer or Niraparib Tosylate GMP API supplier for your needs.

Niraparib Tosylate CoA

A Niraparib Tosylate CoA (Certificate of Analysis) is a formal document that attests to Niraparib Tosylate's compliance with Niraparib Tosylate specifications and serves as a tool for batch-level quality control.

Niraparib Tosylate CoA mostly includes findings from lab analyses of a specific batch. For each Niraparib Tosylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Niraparib Tosylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Niraparib Tosylate EP), Niraparib Tosylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Niraparib Tosylate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty